attana - sensor technologies

Importance of Receptor Accessibility on Drug Efficacy

Nature has recently published an article by Dr. Miriam Dwek's group at University of Westminster showing how alterations in protein glycosylation affect cancer cell behavior perturbing cell adhesion, favoring cell migration and metastasis.

Stockholm, March 23, 2017 – In a new paper from the Cancer Research Group at the University of Westminster headed by Dr Miriam Dwek, the potential role of cellular glycosylation on Herceptin resistance is investigated. Using Attana´s cell based assays, they investigated how Herceptin-HER2 interaction is affected by the presence of glycans on the cell surface. The results show that the glycoprofile of the cell affects the accessibility of HER2-receptor and indicate that glycoprofile can play an important role of Herceptin resistance. Scientific Reports 7, (2017) doi:10.1038/srep43006

The full article is available here.

To learn more about Attana contract research services and our label free cell-based biosensors, please visit www.attana.com or contact our sales department, sales@attana.com.

About Attana:

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. Attana Movie